These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22227647)

  • 21. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.
    Khan S; Carter M
    Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582
    [No Abstract]   [Full Text] [Related]  

  • 22. Patent injunctions in Europe: the return of the pan-European injunction--or how can you get a decision from one court effective in more than one country?
    Freeland R
    Pharm Pat Anal; 2015; 4(6):405-7. PubMed ID: 26580987
    [No Abstract]   [Full Text] [Related]  

  • 23. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 25. India's patent ecosystem - encouraging strong patents or discouraging innovation?
    Harrison C
    Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690
    [No Abstract]   [Full Text] [Related]  

  • 26. Access to drugs: the case of Abbott in Thailand.
    Cawthorne P; Ford N; Wilson D; Kijtiwatchakul K; Purahong V; Tianudom N; Nacapew S
    Lancet Infect Dis; 2007 Jun; 7(6):373-4. PubMed ID: 17521589
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug patent. Court rejects Glaxo's motion to dismiss AZT patent lawsuit.
    AIDS Policy Law; 2003 Aug; 18(15):7. PubMed ID: 14974388
    [No Abstract]   [Full Text] [Related]  

  • 28. The strategy of enantiomer patents of drugs.
    Agranat I; Wainschtein SR
    Drug Discov Today; 2010 Mar; 15(5-6):163-70. PubMed ID: 20116449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An audience with... Thomas Lönngren.
    Lönngren T
    Nat Rev Drug Discov; 2006 Mar; 5(3):182. PubMed ID: 16557656
    [No Abstract]   [Full Text] [Related]  

  • 30. Patents for second medical indications and their potential impact on pharmacare in Canada.
    Scassa T
    Health Law J; 2001; 9():23-59. PubMed ID: 12141223
    [No Abstract]   [Full Text] [Related]  

  • 31. Patent term extensions: issues, challenges and implications for pharmaceuticals.
    Clark L; Beadle D
    Pharm Pat Anal; 2012 Sep; 1(4):427-35. PubMed ID: 24236881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 33. Court dismisses Novartis challenge to Indian patent law.
    Mudur G
    BMJ; 2007 Aug; 335(7614):273. PubMed ID: 17690349
    [No Abstract]   [Full Text] [Related]  

  • 34. Patent watch: EPO rejects reach through claims.
    Nat Rev Drug Discov; 2010 Jan; 9(1):12. PubMed ID: 20043023
    [No Abstract]   [Full Text] [Related]  

  • 35. [Dosing regimens in second medical use patents].
    Suganuma CA
    Cad Saude Publica; 2017 Sep; 33(9):e00096716. PubMed ID: 28977273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novartis challenges India's drug patent laws in Supreme Court.
    Billingsley M
    BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594
    [No Abstract]   [Full Text] [Related]  

  • 37. India to consider raft of new compulsory licences.
    Bagcchi S
    BMJ; 2014 Jan; 348():g1094. PubMed ID: 24464388
    [No Abstract]   [Full Text] [Related]  

  • 38. Court orders development of evidence before ruling on patent.
    AIDS Policy Law; 2003 Jun; 18(11):7. PubMed ID: 12866470
    [No Abstract]   [Full Text] [Related]  

  • 39. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law.
    Thomas JA
    Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014
    [No Abstract]   [Full Text] [Related]  

  • 40. European Medicines Agency pledges to publish clinical reports.
    Watson R
    BMJ; 2014 Oct; 349():g6086. PubMed ID: 25294699
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.